Associations between ALOX, COX, and CRP polymorphisms and breast cancer among Hispanic and non‐Hispanic white women: The breast cancer health disparities study

Chronic inflammation is suggested to be associated with specific cancer sites, including breast cancer. Recent research has focused on the roles of genes involved in the leukotriene/lipoxygenase and prostaglandin/cyclooxygenase pathways in breast cancer etiology. We hypothesized that genes in ALOX/COX pathways and CRP polymorphisms would be associated with breast cancer risk and mortality in our sample of Hispanic/Native American (NA) (1430 cases, 1599 controls) and non‐Hispanic white (NHW) (2093 cases, 2610 controls) women. A total of 104 Ancestral Informative Markers was used to distinguish European and NA ancestry. The adaptive rank truncated product (ARTP) method was used to determine the significance of associations for each gene and the inflammation pathway with breast cancer risk and by NA ancestry. Overall, the pathway was associated with breast cancer risk (PARTP = 0.01). Two‐way interactions with NA ancestry (Padj < 0.05) were observed for ALOX12 (rs2292350, rs2271316) and PTGS1 (rs10306194). We observed increases in breast cancer risk in stratified analyses by tertiles of polyunsaturated fat intake for ALOX12 polymorphisms; the largest increase in risk was among women in the highest tertile with ALOX12 rs9904779CC (Odds Ratio (OR), 1.49; 95% Confidence Interval (CI) 1.14‐1.94, Padj = 0.01). In a sub‐analysis stratified by NSAIDs use, two‐way interactions with NSAIDs use were found for ALOX12 rs9904779 (Padj = 0.02), rs434473 (Padj = 0.02), and rs1126667 (Padj =  0.01); ORs for ALOX12 polymorphisms ranged from 1.55 to 1.64 among regular users. Associations were not observed with breast cancer mortality. These findings could support advances in the discovery of new pathways related to inflammation for breast cancer treatment. © 2014 Wiley Periodicals, Inc.

[1]  B. Klein,et al.  Reproductive windows, genetic loci, and breast cancer risk. , 2014, Annals of epidemiology.

[2]  L. Natarajan,et al.  Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[3]  J. Pankow,et al.  Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study , 2013, Cancer Causes & Control.

[4]  C. Carlson,et al.  Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia , 2013, Genes, chromosomes & cancer.

[5]  R. Wolff,et al.  Associations between TCF7L2 polymorphisms and risk of breast cancer among Hispanic and non-Hispanic White women: the Breast Cancer Health Disparities Study , 2012, Breast Cancer Research and Treatment.

[6]  Jennifer G. Robinson,et al.  Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. , 2012, American journal of human genetics.

[7]  Wei-wei Hu,et al.  Association of ALOX12 and ALOX15 gene polymorphisms with age at menarche and natural menopause in Chinese women , 2012, Menopause.

[8]  R. Wolff,et al.  Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. , 2012, Carcinogenesis.

[9]  Q. Sun,et al.  Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-Analysis , 2011, The International journal of biological markers.

[10]  S. Edge,et al.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype , 2011, Cancer Causes & Control.

[11]  V. Prasad,et al.  Association of a functional polymorphism (Gln261Arg) in 12-lipoxygenase with breast cancer. , 2011, Experimental and therapeutic medicine.

[12]  S. Edge,et al.  Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study , 2011, Breast Cancer Research and Treatment.

[13]  Hong Wu,et al.  Downregulation of 15-lipoxygenase 2 by glucocorticoid receptor in prostate cancer cells. , 2010, International journal of oncology.

[14]  Wen-Huan Xu,et al.  Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.

[15]  F. Olivieri,et al.  Lipoxygenase inhibitors for cancer prevention: promises and risks. , 2010, Current pharmaceutical design.

[16]  I. Romieu,et al.  Moderate physical activity and breast cancer risk: the effect of menopausal status , 2010, Cancer Causes & Control.

[17]  R. Recker,et al.  ALOX12 gene is associated with the onset of natural menopause in white women , 2010, Menopause.

[18]  P. Rosenberg,et al.  Pathway analysis by adaptive combination of P‐values , 2009, Genetic epidemiology.

[19]  S. Keller,et al.  12/15‐Lipoxygenase Products Induce Inflammation and Impair Insulin Signaling in 3T3‐L1 Adipocytes , 2009, Obesity.

[20]  C. Ulrich,et al.  Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Easton,et al.  Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival , 2009, Clinical Cancer Research.

[22]  C. Ulrich,et al.  Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors , 2009, Breast Cancer Research and Treatment.

[23]  M. Etminan,et al.  Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. , 2008, Journal of the National Cancer Institute.

[24]  R. Wolff,et al.  Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women , 2007, Breast Cancer Research and Treatment.

[25]  G. Jin,et al.  Functional Polymorphisms in the Cyclooxygenase 2 (COX-2) Gene and Risk of Breast Cancer in a Chinese Population , 2007, Journal of toxicology and environmental health. Part A.

[26]  J. Buring,et al.  A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study , 2007, Breast Cancer Research.

[27]  A. Neugut,et al.  Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk , 2006, Breast Cancer Research.

[28]  A. Habenicht,et al.  What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? , 2006, International journal of cancer.

[29]  A. Ahmed,et al.  Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. , 2006, Indian journal of cancer.

[30]  B. Paulweber,et al.  The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  E. John,et al.  Migration History, Acculturation, and Breast Cancer Risk in Hispanic Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[32]  R. Millikan,et al.  Cyclooxygenase 2 Polymorphism (Val511Ala), Nonsteroidal Anti-inflammatory Drug Use and Breast Cancer in African American Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[33]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.

[34]  D. Nyholt A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[35]  E. John,et al.  Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  R. Mansel,et al.  Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[37]  M. Stephens,et al.  Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. , 2003, Genetics.

[38]  D. Cox,et al.  Data mining: Efficiency of using sequence databases for polymorphism discovery , 2001, Human mutation.

[39]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[40]  H. Bartsch,et al.  Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. , 1999, Carcinogenesis.

[41]  D. Scollard,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. , 1998, Journal of the National Cancer Institute.

[42]  Xinhua Liu,et al.  Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastatic human breast cancer cell line , 1996, Clinical & Experimental Metastasis.

[43]  Bonnie F. Sloane,et al.  A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. , 1994, Experimental cell research.

[44]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[45]  Pak Chung Sham,et al.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..

[46]  B. Samuelsson Arachidonic acid metabolism: role in inflammation. , 1991, Zeitschrift fur Rheumatologie.

[47]  S. Holm A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[48]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.